logo
Twitter
Discord
Email
logo
Teladoc Health, Inc.

Teladoc Health, Inc.

NYSE•TDOC
CEO: Ms. Mala Murthy
Sector: Healthcare
Industry: Medical - Healthcare Information Services
Listing Date: 2015-06-30
Teladoc Health, Inc. provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems. The BetterHelp segment operates a mental health platform that provides online counseling and therapy services through website, mobile applications, phones, and text-based interactions by its licensed clinicians. The company offers its products and services under the Teladoc, Livongo, and BetterHelp brands. It serves employers, health plans, hospitals and health systems, and insurance and financial services companies, as well as individual members. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. Teladoc Health, Inc. was incorporated in 2002 and is headquartered in Purchase, New York.
Contact Information
2 Manhattanville Road, Suite 203, Purchase, NY, 10577, United States
203-635-2002
www.teladochealth.com
Market Cap
$1.30B
P/E (TTM)
-5.8
37
Dividend Yield
--
52W High
$15.21
52W Low
$6.35
52W Range
11%
Rank69Top 93.9%
1.6
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 1.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q3 2025 Data

Revenue

$626.44M-2.20%
4-Quarter Trend

EPS

-$0.28+40.00%
4-Quarter Trend

FCF

$67.95M-14.02%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Significant Net Loss Improvement Nine months net loss improved $777.66M to $(175.18M), reflecting reduced goodwill impairment charges year-to-date.
Revenue Stability Post-Acquisitions Total revenue $1.89B for nine months; Integrated Care revenue grew 3% despite overall 2% decline.
Strong Cash Position Maintained Cash reserves total $726.25M; operating cash flow stable at $206.62M for the nine months period.
BetterHelp Margin Compression BetterHelp Adjusted EBITDA fell 58% to $23.42M for nine months due to paying user declines.

Risk Factors

BetterHelp Profitability Decline BetterHelp Adjusted EBITDA dropped 58% to $23.42M for nine months due to user declines.
Goodwill Impairment Potential Integrated Care goodwill impairment risk remains if carrying value exceeds fair value post-acquisitions.
CFO Leadership Transition CFO Mala Murthy resigned; CEO Charles Divita III assumes interim CFO duties until replacement found.
Restructuring Cost Recognition Expect charges recognized in Q4 2025 related to efficiency initiatives optimizing operational costs and branding.

Outlook

Efficiency Initiative Implementation Evaluating initiatives to improve efficiency; expecting to begin recognizing related restructuring charges in Q4 2025.
Cash Sufficiency Expected Existing cash sufficient to meet working capital and CapEx needs for at least the next 12 months.
New Credit Facility Secured Entered five-year, $300.0M Revolving Credit Facility to enhance financial and operational flexibility.
Deferred Revenue Recognition Expect to recognize $54.5M in deferred revenue throughout the remainder of 2025 performance obligations.

Peer Comparison

Revenue (TTM)

Teladoc Health, Inc.TDOC
$2.53B
-2.4%
Guardian Pharmacy Services, Inc.GRDN
$1.39B
+18.7%
Progyny, Inc.PGNY
$1.27B
+11.4%

Gross Margin (Latest Quarter)

Phreesia, Inc.PHR
102.6%
+34.9pp
GoodRx Holdings, Inc.GDRX
93.2%
-0.9pp
NovoCure LimitedNVCR
73.2%
-3.9pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
EWTX$2.54B-16.7-30.6%0.7%
PGNY$2.27B42.511.6%3.4%
TXG$1.95B-25.9-10.3%8.5%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-0.7%
Flat Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
100%
Strong Cash Flow

Research & Insights

Next earnings:Feb 25, 2026
|
EPS:-$0.19
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Oct 30, 2025|
    Revenue: $626.44M-2.2%
    |
    EPS: $-0.28+40.0%
    Miss

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Jul 30, 2025|
    Revenue: $631.90M-1.6%
    |
    EPS: $-0.19-96.1%
    Beat

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 1, 2025|
    Revenue: $629.37M-2.6%
    |
    EPS: $-0.53+8.2%
    Miss

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 27, 2025|
    Revenue: $2.57B-1.3%
    |
    EPS: $-5.87-331.6%
    Miss

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Oct 31, 2024|
    Revenue: $640.51M-3.0%
    |
    EPS: $-0.20-42.9%
    Beat

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 1, 2024|
    Revenue: $642.44M-1.5%
    |
    EPS: $-4.92+1130.0%
    Miss

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: Apr 26, 2024|
    Revenue: $646.13M+2.7%
    |
    EPS: $-0.49+16.7%
    Miss

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 23, 2024|
    Revenue: $2.60B+8.1%
    |
    EPS: $-1.36+98.4%
    Miss